Overview

Sirolimus in Previously Treated Idiopathic Multicentric Castleman Disease

Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to understand the impact of sirolimus on idiopathic multicentric Castleman disease.
Phase:
Phase 2
Details
Lead Sponsor:
University of Pennsylvania
Treatments:
Everolimus
Sirolimus